Across multiple studies, BPC-157 consistently decreases levels of pro-inflammatory cytokines like TNF- and IL-6
Most prominently, the substantial reduction in total and visceral adiposity is tightly linked to improved insulin sensitivitya core pathophysiological determinant of MASLD
Several other proteins have shown to upregulate the osteogenic bone healing process [1922]
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Send your inquiry directly to us
